R-3750 for severe lung injury patients on breathing machines
Treatments studied
Part of Lungs & breathing clinical trials.
This trial tests a new drug (R-3750) given by mouth through a feeding tube for patients with severe lung injury (ARDS) that hasn't improved after one to four weeks of intensive care. The goal is to see if the drug helps patients recover better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- You have been diagnosed with severe lung injury (ARDS) that started 7–28 days ago and is not getting better on its own
- You need a breathing machine or similar intensive breathing support right now
- Your doctor believes you can safely receive medicine through a feeding tube in your stomach
- You are not pregnant, breastfeeding, or on ECMO (a heart-lung bypass machine)
- You do not have severe immunosuppression, active infections outside the lungs, or other life-limiting conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called LEAF-4L6715 to see if it helps people with severe acute respiratory distress syndrome (ARDS), a serious lung condition. If you are on a breathing machine and meet the criteria below, you may be able to join.
This trial tests a new medicine called MRG-001 for people with severe lung injury (ARDS) who need breathing support. It aims to help the lungs heal and reduce inflammation.
This trial is testing new treatments for people with ARDS, a serious lung condition. The goal is to find therapies that help patients breathe better and recover faster. If you or a loved one has ARDS, this study may offer access to experimental treatments.
This pilot study tests NOA-001, a treatment given to people with ARDS (a serious lung condition) who are already on a breathing machine. It looks at whether the treatment can improve outcomes in ARDS caused by either non-COVID illnesses or COVID-19.
This Phase 2 trial tests Rhu-pGSN in adults with acute respiratory distress syndrome (ARDS) caused by an infection. If you qualify, the study may help determine whether the drug improves outcomes in this short-term, life-threatening lung condition.
This trial tests a more tailored way to set the amount of air delivered by a ventilator in people with severe ARDS. The goal is to see if personalized breathing settings can improve breathing and heart-related monitoring while patients are in intensive care.
Hear when a new Acute Respiratory Distress Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.